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Abstract 
Based on newer data from randomized controlled trials and 
meta-analyses, the previously controversial and highly debated 
issue of patent foramen ovale (PFO) closure in patients with 
cryptogenic stroke is finally settled in favor of closure over 
medical therapy for the secondary prevention of cryptogenic 
stroke attributable to paradoxical embolism. One PFO closure 
device has finally received FDA approval in October 2016.  
Rhythmos 2017; 12(4):60-62.   
Key Words: cryptogenic stroke; paradoxical embolism; patent 
foramen ovale; percutaneous closure  
Abbreviations: PFO = patent foramen ovale; RCT=randomized 
controlled trial; RoPe = risk of paradoxical embolism  
PFO / Initial PFO Closure RCTs 
It is estimated that every 1 in 4 individuals in the 
general population has a patent foramen ovale (PFO), 1, 2 
which by itself does not increase the risk of ischemic 
stroke; 3 however, PFO is more prevalent among patients 
who have suffered a cryptogenic ischemic stroke, parti-
cularly among younger patients. 4 Although thrombi have 
been caught in the act with imaging techniques depicting 
them in transit through a PFO, 5, 6 the clinical benefit of 
percutaneous closure of a PFO after a cryptogenic stroke 
has been debated for the last two decades.7, 8 The first three 
randomized controlled trials (RCTs) were finally and 
belatedly published (CLOSURE I, PC-Trial, RESPECT), 
but were not definitively conclusive. 9-12 The extended 
follow-up of the RESPECT trial, however, provided the 
data that the FDA demanded. 13   
FDA Approval /Newer Data 
 On October 28, 2016, the FDA of the U.S. granted 
approval for the Amplatzer PFO occluder for patients with 
cryptogenic stroke which is determined to have been 
probably caused by a paradoxical embolism 
(http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncem
ents/ucm527096.htm). This decision was based, as already 
mentioned, on the extended follow-up (median 5.9 years) 
of the RESPECT RCT which evaluated 499 participants 
aged 18 to 60 years old who were treated with the 
Amplatzer PFO Occluder plus antithrombotic medications 
compared to 481 participants who were treated with 
antithrombotic drugs alone (Table 1). 13 While the rate of 
new strokes in both treatment groups was very low, the 
study found a 45% reduction in the rate of new strokes in 
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participants using the Amplatzer PFO Occluder compared 
to participants taking only antithrombotic medications 
(recurrent ischemic stroke occurred in 18 patients in the 
PFO closure group and in 28 patients in the medical-
therapy group, resulting in rates of 0.58 events per 100 
patient-years and 1.07 events per 100 patient- years, 
respectively; hazard ratio-HR with PFO closure vs medical 
therapy, 0.55; P = 0.046 by the log-rank test). Recurrent 
ischemic stroke of undetermined cause occurred in 10 
patients in the PFO closure group and in 23 patients in the 
medical-therapy group (HR 0.38; P=0.007).  
 In a pooled analysis of the initial 3 RCTs (CLOSURE 
I, PC-Trial, RESPECT) employing 2 devices (STARFlex, 
NMT Medical, Inc., Boston, Massachusetts; and 
Amplatzer PFO Occluder, AGA Medical/St. Jude Medical, 
St. Paul, Minnesota) in 2,303 patients, closure was not 
significantly associated with the primary composite 
outcome (stroke, TIA, or death). 14  The difference became 
significant after covariate adjustment (HR: 0.68; p=0.049). 
For the outcome of stroke, all comparisons were 
statistically significant, with unadjusted and adjusted HRs 
of 0.58 (p = 0.043) and 0.58 (p = 0.044), respectively. In 
analyses limited to the 2-disc occluder device trials, the 
effect of closure was not significant for the composite 
outcome, but was for the stroke outcome (unadjusted HR: 
0.39; p = 0.013). Atrial fibrillation (AF) was more common 
among closure patients. The authors concluded that among 
patients with PFO and cryptogenic stroke, closure reduced 
recurrent stroke and had a statistically significant effect on 
the composite of stroke, transient ischemic attack, and 
death in adjusted but not unadjusted analyses.   
Recent  RCTs 
In 2017, the results of two additional RCTs were 
reported (Table 1). 15, 16 The CLOSE trial (2017), included 
663 patients aged 16 - 60 years who had had a recent stroke 
attributed to PFO, with an associated atrial septal 
aneurysm or large interatrial shunt, randomized to 
transcatheter PFO closure plus long-term antiplatelet 
therapy (PFO closure group), antiplatelet therapy alone 
(antiplatelet-only group), or oral anticoagulation 
(anticoagulation group) (randomization group 1). 15 
Patients with contraindications to anticoagulants or to PFO 
closure were randomly assigned to the alternative non-
contraindicated treatment or to antiplatelet therapy 
(randomization groups 2 and 3). The primary outcome was 
occurrence of stroke. Over a mean of 5.3±2.0 years, no 
stroke occurred among the 238 patients in the PFO closure 
group, whereas stroke occurred in 14 of the 235 patients in 
the antiplatelet- only group (hazard ratio, 0.03; P<0.001). 
Procedural complications from PFO closure occurred in 14 
patients (5.9%). The rate of AF was higher in the PFO 
closure group than in the antiplatelet-only group (4.6% vs. 
0.9%, P = 0.02). The number of serious adverse events did 
not differ significantly between the treatment groups (P = 
0.56). In the analysis of randomization groups 1 and 3, 
stroke occurred in 3 of 187 patients assigned to oral 
anticoagulants and in 7 of 174 patients assigned to 
antiplatelet therapy alone. The authors concluded that 
among patients who had had a recent cryptogenic stroke 
attributed to PFO with an associated atrial septal aneurysm 
or large interatrial shunt, the rate of stroke recurrence was 
lower among those assigned to PFO closure combined with 
antiplatelet therapy than among those assigned to 
antiplatelet therapy alone.  
The REDUCE trial (2017) enrolled 664 patients (mean 
age 45.2 years) with cryptogenic stroke, of whom 81% had 
moderate or large interatrial shunts. 16 Over a median of 
3.2 years, ischemic stroke occurred in 6 of 441 patients 
(1.4%) in the PFO closure group and in 12 of 223 patients 
(5.4%) in the antiplatelet-only group (hazard ratio, 0.23; P 
= 0.002). The incidence of new brain infarctions was lower 
in the PFO closure group than in the antiplatelet-only 
group (22 patients or 5.7% vs 20 patients or 11.3%; relative 
risk 0.51; P=0.04), but the incidence of silent brain infa-
rction did not differ significantly between the study groups 
(P = NS). Serious adverse events occurred in 23.1% in the 
PFO closure group and in 27.8% in the antiplatelet-only 
group (P=0.22). Serious device-related adverse events 
occurred in 6 patients (1.4%) in the PFO closure group, and 
AF occurred in 29 patients (6.6%) after PFO closure.   
Updated Meta-Analysis 
A recent updated meta-analysis comprising all 5 RCTs 
(n = 3,440; mean follow-up 2.9 years) indicated that, 
compared with medical therapy, risk of recurrent stroke 
was lower with closure (2.2% vs 4%; RR: 0.54; I2 = 41%; 
p = 0.02). 17 Atrial fibrillation risk was higher with closure 
(4% vs 0.7%; RR: 4.60; I2 = 28%; p < 0.01). Risk of AF 
was not different with the Amplatzer PFO occluder 
(Abbott, Chicago, Illinois) (RR: 2.29; I2 =0%; p = 0.64) 
but was significant with the STARFlex (NMT Medical, 
Boston, Massachusetts) (RR: 7.92; p < 0.01) and Gore (W. 
L. Gore & Associates, Flagstaff, Arizona) (RR 14.66; p < 
0.01) devices. There was no publication bias for both 
primary outcomes (p = 0.11 and p = 0.14, respectively).  
Procedure of PFO Closure 
The procedure of PFO closure is relatively simple and 
in experienced hands it could be performed even without 
transesophageal echocardiography (TEE) guidance or use 
of general anesthesia, using only local anesthesia and 
fluoroscopy guidance.18, 19 A shared decision-making 
approach with involvement of patient and patient’s family 
appears to be the most appropriate strategy to follow.  
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Conclusion 
The accumulated evidence is now compelling for the 
benefit and superiority of PFO closure over medical 
therapy in patients with cryptogenic strokes for the 
secondary prevention of stroke. FDA granted approval in 
2016 for one type of such closure device to be employed 
for these procedures and thus it behooves us to apply this 
therapeutic modality in the most appropriate and prudent 
strategy in the management of patients with cryptogenic 
strokes which are deemed secondary to paradoxical 
embolism. Selecting the appropriate patient is of 
paramount importance, since there are several competing 
potential causes of stroke, 20 and only those related to 
paradoxical embolism are amenable to PFO closure. Risk 
scores have been proposed which may identify patients 
with probable paradoxical embolism (e.g. RoPE: risk of 
paradoxical embolism) and enable the selection of those 
with a high attributable recurrence risk especially likely to 
benefit from PFO closure. 21   
Table 1. Studies Supporting PFO Closure over Medical 
Therapy for Cryptogenic Stroke  
Study/Year Type / Device No of 
patients 
Outcome 
RESPECT, 
extended / 
2016 13 
RCT / 
AMPLATZER  
980 ↓strokes by 
45% / NNT: 42 
by 5 years 
Pooled 
analysis (3 
RCTs)/ 2016 14  
Pooled analysis / 
STARFLEX & 
AMPLATZER  
2303 ↓strokes by 
42% 
CLOSE / 2017 
15  
RCT / 11 different 
devices 
663 ↓strokes by 
99.7% / NNT: 
20 by 5 years 
REDUCE / 
2017 16  
RCT / HELEX or 
GORE  
664 ↓strokes by 
77% / NNT: 29 
by 2 years 
Meta-analysis 
(5 RCTs) / 
2017 17  
Meta-analysis / 
Several  
3440 ↓strokes by 
46% 
NNT = number needed to treat; PFO = patent foramen ovale; 
RCTs = randomized controlled trials  
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